Non-viral COVID-19 vaccine delivery systems Drug

Kyung Soo Park,Xiaoqi Sun,Marisa E. Aikins,J. Moon
2021-01-01
Abstract:The novel corona virus termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread throughout the globe at a formidable speed, causing tens of millions of cases and more than one million deaths in less than a year of its report in December 2019. Since then, companies and research institutions have raced to develop SARS-CoV-2 vaccines, ranging from conventional viral and protein-based vaccines to those that are more cutting edge, including DNA- and mRNA-based vaccines. Each vaccine exhibits a different potency and du- ration of ef fi cacy, as determined by the antigen design, adjuvant molecules, vaccine delivery platforms, and immunization method. In this review, we will introduce a few of the leading non-viral vaccines that are under clinical stage development and discuss delivery strategies to improve vaccine ef fi cacy, duration of protection, safety, and mass vaccination.
What problem does this paper attempt to address?